Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
| Revenue (TTM) | $56.22M |
| Gross Profit (TTM) | $42.45M |
| EBITDA | $6.62M |
| Operating Margin | 12.90% |
| Return on Equity | 12.60% |
| Return on Assets | 3.31% |
| Revenue/Share (TTM) | $1.47 |
| Book Value | $1.99 |
| Price-to-Book | 8.37 |
| Price-to-Sales (TTM) | 11.06 |
| EV/Revenue | 10.52 |
| EV/EBITDA | 54.93 |
| Quarterly Earnings Growth (YoY) | 200.00% |
| Quarterly Revenue Growth (YoY) | 34.60% |
| Shares Outstanding | $40.13M |
| Float | $28.44M |
| % Insiders | 6.03% |
| % Institutions | 29.84% |
Volatility is currently expanding
Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care
BWAY, HTLD and NCNO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14th, 2026.
HTLD, MEOH, NCNO, JD and BWAY have been added to the Zacks Rank #1 (Strong Buy) List on July 14th, 2026.
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTSD
Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment from 85% to 0% Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment from 85% to 0%
Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access to transformative care Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access to transformative care
Brainsway NASDAQ: BWAY reported a strong start to 2026, with first-quarter revenue rising 35% year over year as the company expanded placements of its Deep TMS systems and continued to build its recurring revenue base.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BWAY and any ticker you trade — then tracks every position and per-strategy win rate.
